Eli Lilly’s Mounjaro is significantly more effective than Novo Nordisk’s Ozempic in producing weight loss in patients with overweight or obesity, a new real-world study found.
Thank you for reading this post, don't forget to subscribe!In an analysis of 18,000 patients, those taking Mounjaro were three times more likely than those taking Ozempic to achieve 15% weight loss, according to the study by Truveta Research, which analyzes de-identified patient data from a collective of health systems. After one year of treatment, the patients taking Mounjaro lost an average 15.2% of their…
Master your money.
Subscribe to MarketWatch.
Get this article and all of MarketWatch.
Access from any device. Anywhere. Anytime.
Already a subscriber?
Log In
